Bluebird bio Inc (NASDAQ:BLUE) concluded the trading at $1.16 on Thursday, April 11, with a fall of -2.52% from its closing price on previous day.
Taking a look at stock we notice that its last check on previous day was $1.19 and 5Y monthly beta was reading 0.80. Considering stock’s 52-week price range provides that BLUE hit a high price of $5.53 and saw its price falling to a low level of $0.88 during that period. Over a period of past 1-month, stock came subtracting -13.75% in its value.
With its current market valuation of $223.58 million, Bluebird bio Inc is set to declare its quarterly results on Mar 27, 2024 – Apr 01, 2024. Analysts are in estimates of -$0.64 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -$1.76 for 2023 with estimates of that growing to -$1.61 in next year. These estimates are suggesting current year growth of 48.10% for EPS and 8.50% growth next year.
Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of $10.16 million. They suggested that in the process company could generate revenue of as low as $7.7 million which could climb up to $17.3 million to hit a high. The average estimate is representing an increase of 16,287.10% in sales growth from that of posted by the company in the same quarter of last year. In keeping analyst consensus estimate with, company is forecasted to be making an annual revenue of $35.3 million in 2023, which will be 881.40% more from revenue generated by the company last year.
In last 7 days, analysts came adjusting their opinions about stock’s EPS with 1 upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review BLUE stock’s current outlook then short term indicators are assigning it an average of 50% Sell, while medium term indicators are categorizing the stock at an average of 100% Sell. Long term indicators are suggesting an average of 100% Sell for it.
Digging deeper we become aware of the PEG ratio of the BLUE stock which is currently positioned at 0. It further provides that stock’s current price level is -11.16% away from its 20-day simple moving average and is -7.54% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 42.74 while volatility remained at 7.26% over the past week which changes to 8.83% when measuring it over the past month. Beta is valued at 0.77, while measure of average true range or ATR is currently at 0.13.
Having a second look at Bluebird bio Inc (NASDAQ:BLUE) provides that stock’s average daily trading volume for 3 months was 8.88 million, while it jumped to 4.0 million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 192.74 million.
The percentage of outstanding shares held by the insiders is 1.51% while it is 67.33% for the institutional holders. The figures also indicate that as of Mar 15, 2024, number of stock’s short shares was 34.04 million which implies a short ratio of 2.91. This shows up a 17.66% of Short Interest in company’s outstanding shares on the day. In March the standing of shares short improved as it was 28.59 million in the previous month. Subtraction of -15.94% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.
